Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zogenix Inc (ZGNX)

Zogenix Inc (ZGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022

Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS...

ZGNX : 26.68 (+1.60%)
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full yearFINTEPLA® net product sales of $23.5 million in the fourth quarter...

ZGNX : 26.68 (+1.60%)
Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases

Symptoms of mitochondrial diseases, such as Thymidine Kinase 2 deficiency (TK2d), can vary widely and mimic other rare and common diseases, making...

ZGNX : 26.68 (+1.60%)
Why Zogenix Flew Higher Before Leveling Off This Week

The company attracts a determined suitor from abroad.

ZGNX : 26.68 (+1.60%)
UCBJF : 179.0500 (+0.31%)
Zogenix (ZGNX) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Zogenix, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ZGNX

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Zogenix, Inc. (NASDAQ: ZGNX) to UCB is fair to Zogenix shareholders. Under the terms of the agreement, UCB would...

ZGNX : 26.68 (+1.60%)
Why Zogenix Stock Is on Fire Today

A buyout deal is lighting a fire underneath the biotech's shares today.

ZGNX : 26.68 (+1.60%)
Pre-Market Brief: Stock Indexes Swing Higher on Q4 Earnings Optimism

Morning Markets March S&P 500 futures this morning recovered from a 4-week low in overnight trade and are up +0.40%. Optimism about Q4 corporate earnings results is helping to push stocks higher this...

MS : 99.30 (-0.54%)
BAC : 39.62 (+0.18%)
SOFI : 8.11 (-0.12%)
PG : 173.92 (-1.11%)
ZGNX : 26.68 (+1.60%)
FREY : 1.0900 (+0.93%)
USB : 45.18 (+1.12%)
OESX : 0.8500 (-0.12%)
CSCO : 50.57 (-0.08%)
LEN : 188.43 (-0.49%)
KBH : 86.62 (-0.15%)
TOL : 150.14 (-0.35%)
Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome

EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that...

ZGNX : 26.68 (+1.60%)
Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome

EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare...

ZGNX : 26.68 (+1.60%)
Zogenix Reports Granting of Inducement Awards

EMERYVILLE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of...

ZGNX : 26.68 (+1.60%)

Barchart Exclusives

Dividend Aristocrats: The Best of the Best for Stable Income
Dividend Aristocrats' ability to increase their dividends indicates strong earnings and a solid business foundation, which lowers investment risk. Moreover, their consistent earnings growth often enables them to outperform broader market indices. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar